[{"uuid": "9930afcb-d293-3906-82ff-5db533a3b022", "title": "Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/bicara-therapeutics-presents-phase-1-130000111.html", "providerPublishTime": 1737982800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/kJz8ysCNim5LK9mFt5PVZA--~B/aD00MTM7dz0xNDQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b62515267c34b80af59ee5dc341da442", "width": 1442, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/LoCDPgEPSai9GCujQuXjkQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b62515267c34b80af59ee5dc341da442", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCAX"]}, {"uuid": "514a3187-7948-39e3-ba90-4b6a2435479b", "title": "Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/514a3187-7948-39e3-ba90-4b6a2435479b/early-success-for-mbx-in.html", "providerPublishTime": 1736349387, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/1wRdv1yPeKcbXd4AwAxBjQ--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/1332f9e266219535359823641a1d835a", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/3MqguLenMEFO1N81Pf82ZA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/1332f9e266219535359823641a1d835a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCAX"]}, {"uuid": "27e8d1c5-4d7f-34b9-83e4-63824c8b57e4", "title": "Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/bicara-therapeutics-reports-third-quarter-123000595.html", "providerPublishTime": 1731414600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/kJz8ysCNim5LK9mFt5PVZA--~B/aD00MTM7dz0xNDQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b62515267c34b80af59ee5dc341da442", "width": 1442, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/LoCDPgEPSai9GCujQuXjkQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b62515267c34b80af59ee5dc341da442", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCAX"]}, {"uuid": "8bb5cc71-b980-3478-a182-783fa2bef81f", "title": "Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/bicara-therapeutics-present-stifel-2024-210100733.html", "providerPublishTime": 1731358860, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/kJz8ysCNim5LK9mFt5PVZA--~B/aD00MTM7dz0xNDQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b62515267c34b80af59ee5dc341da442", "width": 1442, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/LoCDPgEPSai9GCujQuXjkQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b62515267c34b80af59ee5dc341da442", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCAX"]}, {"uuid": "7bf5c4ac-0fe6-35f7-8050-ca84be87d59b", "title": "Bicara Therapeutics' Q3 Loss Narrows", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/bicara-therapeutics-apos-q3-loss-140638442.html", "providerPublishTime": 1731420398, "type": "STORY", "relatedTickers": ["BCAX"]}]